Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Osanni Bio closes $190 million Series B financing led by Patient Square Capital to advance its innovative pipeline in ophthalmology and cardiology.

PRIVATEJun 23, 2026•about 2 months ago

Amount Raised

$190 Million

Round Type

Series B

San FranciscoBiotechnologyHealth CareTherapeutics

Investors

Retinal Degeneration FundInvus OpportunitiesHorowitz GroupPatient Square Capital

Description

Osanni Bio LLC has announced the close of a $190 million Series B financing led by Patient Square Capital. The financing proceeds will be used to advance the company's current pipeline and enhance its discovery and development process. Existing investors also participated in the round. Osanni aims to leverage modern technology for efficient medicine discovery.

Company Information

Company

Osanni Bio

Location

San Francisco, California, United States

About

Osanni Bio is a development-stage therapeutics platform focused on reinventing the discovery and development of new medicines. The company utilizes biodesign-inspired innovation and modern technology for capital-efficient drug development. Osanni is advancing programs in ophthalmology, cardiology, and other therapeutic areas. Its innovative architecture combines centralized scientific depth with the agility of independent companies to foster transformative medicine creation.

Predictive Intelligence
Strategic

ML-powered predictions for Osanni Bio's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.